Ignite Creation Date:
2024-05-05 @ 11:34 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00086164
Status:
TERMINATED
Last Update Posted:
2005-07-19
First Post:
2004-06-25
Brief Title:
Prevention of Vascular Access Graft Failure in Patients With Chronic Renal Failure Requiring Hemodialysis
Sponsor:
Anesiva Inc
Organization:
Anesiva Inc
Study Overview
Official Title:
A Phase 12 Multi-Center Randomized Double-Blind Placebo-Controlled Pilot Trial to Assess the Effect of Treatment of the Recipient Vein of a Polytetrafluoroethylene PTFE Vascular Access Graft With Two Concentrations of E2F Decoy as Compared to Placebo on Neointimal Hyperplasia and the Preservation of Graft Function in Patients With Chronic Renal Failure Requiring Hemodialysis
Status:
TERMINATED
Status Verified Date:
2005-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the effect of recipient vein pretreatment of edifoligide E2F Decoy compared to placebo on graftrecipient vein stenosis in polytetrafluoroethylene PTFE vascular access grafts placed for hemodialysis at 6 months after enrollment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None